VEGFA and hepatocellular carcinoma: Interestingly, Tsukiya et al. showed that a 5% decrease in plasma VEGF levels at 8 weeks from baseline was an independent prognostic factor associated with 1-year survival after Sorafenib treatment in a small cohort of HCC patients (n = 63) [131].